
ONC Stock Forecast & Price Target
ONC Analyst Ratings
Bulls say
BeOne Medicines is favored because Brukinsa remains a durable market leader, generating about $1.39B in 3Q26 global revenue and roughly 74% of total revenue, while still expanding across indications and geographies despite competition from AbbVie and AstraZeneca. Its outlook is further supported by improving financial execution, including 3Q26 total revenue of $1.9B, diluted EPS of $3.28, and $5.87B in cash, alongside raised full-year guidance for revenue, operating income, and expenses. Beyond the core hematology franchise, management is advancing more than 50 drugs in clinical trials, with promising solid-tumor programs and next-wave assets like sonrotoclax and tacabrutideg creating additional long-term growth optionality.
Bears say
BeOne Medicines is exposed to meaningful fundamental risk because Brukinsa contributes 74% of total revenue, leaving the business highly dependent on one asset while newer products like Beqalzi and Tevimbra remain largely China-centric. The bearish thesis is reinforced by the possibility that sonro fails in Phase 3 and never reaches a registrational path, while other pipeline assets underperform and fail to differentiate in a crowded heme-onc market where AbbVie and AstraZeneca pressure the BTK space. With drug development, regulatory delays, competitive setbacks, and heavy pipeline cash burn all capable of impairing growth, the company’s valuation could be constrained even if commercial execution is solid.
This aggregate rating is based on analysts' research of BeOne Medicines Ltd and is not a guaranteed prediction by Public.com or investment advice.
ONC Analyst Forecast & Price Prediction
Start investing in ONC
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About BeOne Medicines Ltd (ONC) Forecast
ONC Analyst Forecast & Price Prediction
Start investing in ONC
Order type
Buy in
Order amount
Est. shares
0 shares